These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18554581)

  • 1. Association between acetylcholinesterase and beta-amyloid peptide in Alzheimer's cerebrospinal fluid.
    García-Ayllón MS; Silveyra MX; Sáez-Valero J
    Chem Biol Interact; 2008 Sep; 175(1-3):209-15. PubMed ID: 18554581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease.
    García-Ayllón MS; Silveyra MX; Andreasen N; Brimijoin S; Blennow K; Sáez-Valero J
    J Neurochem; 2007 Jun; 101(6):1701-11. PubMed ID: 17326766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
    Sáez-Valero J; Fodero LR; Sjögren M; Andreasen N; Amici S; Gallai V; Vanderstichele H; Vanmechelen E; Parnetti L; Blennow K; Small DH
    J Neurosci Res; 2003 May; 72(4):520-6. PubMed ID: 12704813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
    Parnetti L; Amici S; Lanari A; Romani C; Antognelli C; Andreasen N; Minthon L; Davidsson P; Pottel H; Blennow K; Gallai V
    Neurol Sci; 2002 Sep; 23 Suppl 2():S95-6. PubMed ID: 12548360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease.
    Nitsch RM; Deng M; Tennis M; Schoenfeld D; Growdon JH
    Ann Neurol; 2000 Dec; 48(6):913-8. PubMed ID: 11117548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease.
    Parnetti L; Chiasserini D; Andreasson U; Ohlson M; Hüls C; Zetterberg H; Minthon L; Wallin AK; Andreasen N; Talesa VN; Blennow K
    Acta Neurol Scand; 2011 Aug; 124(2):122-9. PubMed ID: 20880294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease.
    Nakamura T; Shoji M; Harigaya Y; Watanabe M; Hosoda K; Cheung TT; Shaffer LM; Golde TE; Younkin LH; Younkin SG
    Ann Neurol; 1994 Dec; 36(6):903-11. PubMed ID: 7998778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro.
    Ono K; Noguchi M; Matsumoto Y; Yanase D; Iwasa K; Naiki H; Yamada M
    Neurobiol Dis; 2005 Nov; 20(2):233-40. PubMed ID: 16242632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
    Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
    Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties.
    Marksteiner J; Pirchl M; Ullrich C; Oberbauer H; Blasko I; Lederer W; Hinterhuber H; Humpel C
    Pharmacology; 2008; 82(3):214-20. PubMed ID: 18810245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome.
    Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K
    Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid acetylcholinesterase activity in senile dementia of the Alzheimer type.
    Tune L; Gucker S; Folstein M; Oshida L; Coyle JT
    Ann Neurol; 1985 Jan; 17(1):46-8. PubMed ID: 3985585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.
    Portelius E; Zetterberg H; Andreasson U; Brinkmalm G; Andreasen N; Wallin A; Westman-Brinkmalm A; Blennow K
    Neurosci Lett; 2006 Dec; 409(3):215-9. PubMed ID: 17049739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.
    Berson A; Knobloch M; Hanan M; Diamant S; Sharoni M; Schuppli D; Geyer BC; Ravid R; Mor TS; Nitsch RM; Soreq H
    Brain; 2008 Jan; 131(Pt 1):109-19. PubMed ID: 18056160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.
    Deutsch SI; Mohs RC; Levy MI; Rothpearl AB; Stockton D; Horvath T; Coco A; Davis KL
    Biol Psychiatry; 1983 Dec; 18(12):1363-73. PubMed ID: 6661467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice.
    Dinamarca MC; Arrázola M; Toledo E; Cerpa WF; Hancke J; Inestrosa NC
    Chem Biol Interact; 2008 Sep; 175(1-3):142-9. PubMed ID: 18599028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
    Hampel H; Shen Y
    Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
    Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How well does the CSF inform upon pathology in the brain in Creutzfeldt-Jakob and Alzheimer's diseases?
    Weller RO
    J Pathol; 2001 May; 194(1):1-3. PubMed ID: 11329133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.